Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
You may also be interested in...
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
Takeda and Zydus Cadila are stepping into the fray to develop a vaccine for chikungunya, an increasingly crowded segment that now has over a dozen candidates in various stages of development.